Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
6.44
+0.05 (0.78%)
Nov 4, 2025, 11:50 AM EST - Market open
Evolus Employees
Evolus had 332 employees as of December 31, 2024. The number of employees increased by 59 or 21.61% compared to the previous year.
Employees
332
Change (1Y)
59
Growth (1Y)
21.61%
Revenue / Employee
$837,172
Profits / Employee
-$186,732
Market Cap
416.57M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 332 | 59 | 21.61% |
| Dec 31, 2023 | 273 | 58 | 26.98% |
| Dec 31, 2022 | 215 | 48 | 28.74% |
| Dec 31, 2021 | 167 | 48 | 40.34% |
| Dec 31, 2020 | 119 | -116 | -49.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EOLS News
- 7 days ago - Evolus to Participate in 2025 Stifel Healthcare Conference - Business Wire
- 13 days ago - Evolus to Report Third Quarter Financial Results on November 5, 2025 - Business Wire
- 24 days ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch - PRNewsWire
- 7 weeks ago - Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer - Business Wire
- 2 months ago - Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp - Business Wire
- 2 months ago - Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product - Business Wire